Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

vTv Therapeutics (VTVT) Depreciation & Amortization (CF) (2016 - 2025)

vTv Therapeutics' Depreciation & Amortization (CF) history spans 12 years, with the latest figure at $2000.0 for Q4 2025.

  • For Q4 2025, Depreciation & Amortization (CF) fell 90.91% year-over-year to $2000.0; the TTM value through Dec 2025 reached $16000.0, down 82.02%, while the annual FY2025 figure was $16000.0, 82.02% down from the prior year.
  • Depreciation & Amortization (CF) for Q4 2025 was $2000.0 at vTv Therapeutics, roughly flat from $2000.0 in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $31000.0 in Q4 2022 and bottomed at $2000.0 in Q3 2025.
  • The 5-year median for Depreciation & Amortization (CF) is $22000.0 (2021), against an average of $19200.0.
  • The largest annual shift saw Depreciation & Amortization (CF) soared 40.91% in 2022 before it plummeted 90.91% in 2025.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $22000.0 in 2021, then surged by 40.91% to $31000.0 in 2022, then fell by 25.81% to $23000.0 in 2023, then decreased by 4.35% to $22000.0 in 2024, then tumbled by 90.91% to $2000.0 in 2025.
  • Per Business Quant, the three most recent readings for VTVT's Depreciation & Amortization (CF) are $2000.0 (Q4 2025), $2000.0 (Q3 2025), and $3000.0 (Q2 2025).